Does the media favor DGX or HSIC?

In the previous week, Henry Schein had 4 more articles in the media than Quest Diagnostics. MarketBeat recorded 15 mentions for Henry Schein and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat Henry Schein's score of 0.83 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, DGX or MEDP?

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 1.95 $992M $9.05 21.46 Medpace $2.53B 5.09 $451.12M $15.91 28.34

Is DGX or MEDP more profitable?

Medpace has a net margin of 17.19% compared to Quest Diagnostics' net margin of 9.07%. Medpace's return on equity of 120.89% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.07% 15.60% 7.06% Medpace 17.19% 120.89% 24.79%

Does the media prefer DGX or MEDP?

In the previous week, Medpace had 23 more articles in the media than Quest Diagnostics. MarketBeat recorded 34 mentions for Medpace and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat Medpace's score of 0.27 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 7 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DGX or AMN?

In the previous week, AMN Healthcare Services had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 14 mentions for AMN Healthcare Services and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat AMN Healthcare Services' score of 0.17 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LH or DGX?

In the previous week, Labcorp and Labcorp both had 11 articles in the media. Quest Diagnostics' average media sentiment score of 1.06 beat Labcorp's score of 0.93 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DVA or DGX more profitable?

Quest Diagnostics has a net margin of 9.07% compared to DaVita's net margin of 5.65%. Quest Diagnostics' return on equity of 15.60% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 5.65% -270.37% 4.87% Quest Diagnostics 9.07% 15.60% 7.06%

Does the media refer more to DVA or DGX?

In the previous week, Quest Diagnostics had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Quest Diagnostics and 4 mentions for DaVita. Quest Diagnostics' average media sentiment score of 1.06 beat DaVita's score of 0.96 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quest Diagnostics (DGX) Competitors

$194.17 +1.01 (+0.52%)

Closing price 03:58 PM Eastern

Extended Trading

$194.05 -0.12 (-0.06%)

As of 06:32 PM Eastern

Compare

DGX vs. HSIC, MEDP, AMN, LH, and DVA

Should you buy Quest Diagnostics stock or one of its competitors? MarketBeat compares Quest Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and DaVita (DVA). These companies are all part of the "medical" sector.

How does Quest Diagnostics compare to Henry Schein?

Quest Diagnostics (NYSE:DGX) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Quest Diagnostics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

Quest Diagnostics has a net margin of 9.07% compared to Henry Schein's net margin of 2.95%. Quest Diagnostics' return on equity of 15.60% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
Henry Schein	2.95%	15.44%	5.53%

Quest Diagnostics has higher earnings, but lower revenue than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	1.95	$992M	$9.05	21.46
Henry Schein	$13.18B	0.65	$398M	$3.31	22.88

In the previous week, Henry Schein had 4 more articles in the media than Quest Diagnostics. MarketBeat recorded 15 mentions for Henry Schein and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat Henry Schein's score of 0.83 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 0.9% of Henry Schein shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quest Diagnostics currently has a consensus target price of $216.58, indicating a potential upside of 11.54%. Henry Schein has a consensus target price of $86.83, indicating a potential upside of 14.65%. Given Henry Schein's higher probable upside, analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Summary

Quest Diagnostics beats Henry Schein on 9 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Quest Diagnostics (NYSE:DGX) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Quest Diagnostics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	1.95	$992M	$9.05	21.46
Medpace	$2.53B	5.09	$451.12M	$15.91	28.34

Medpace has a net margin of 17.19% compared to Quest Diagnostics' net margin of 9.07%. Medpace's return on equity of 120.89% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
Medpace	17.19%	120.89%	24.79%

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Quest Diagnostics presently has a consensus price target of $216.58, suggesting a potential upside of 11.54%. Medpace has a consensus price target of $467.08, suggesting a potential upside of 3.61%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Medpace had 23 more articles in the media than Quest Diagnostics. MarketBeat recorded 34 mentions for Medpace and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat Medpace's score of 0.27 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	7 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medpace beats Quest Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

Quest Diagnostics (NYSE:DGX) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quest Diagnostics has a net margin of 9.07% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	1.95	$992M	$9.05	21.46
AMN Healthcare Services	$3.42B	0.34	-$95.70M	-$0.87	N/A

Quest Diagnostics presently has a consensus target price of $216.58, indicating a potential upside of 11.54%. AMN Healthcare Services has a consensus target price of $25.29, indicating a potential downside of 16.48%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Quest Diagnostics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

In the previous week, AMN Healthcare Services had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 14 mentions for AMN Healthcare Services and 11 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.06 beat AMN Healthcare Services' score of 0.17 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.8%. AMN Healthcare Services pays an annual dividend of $1.20 per share and has a dividend yield of 4.0%. Quest Diagnostics pays out 38.0% of its earnings in the form of a dividend. AMN Healthcare Services pays out -137.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years. AMN Healthcare Services is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Quest Diagnostics beats AMN Healthcare Services on 13 of the 19 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Labcorp (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

95.9% of Labcorp shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 0.8% of Labcorp shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Quest Diagnostics has lower revenue, but higher earnings than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.52	$876.50M	$11.29	22.98
Quest Diagnostics	$11.04B	1.95	$992M	$9.05	21.46

Quest Diagnostics has a net margin of 9.07% compared to Labcorp's net margin of 6.66%. Labcorp's return on equity of 16.29% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.66%	16.29%	7.62%
Quest Diagnostics	9.07%	15.60%	7.06%

Labcorp has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Labcorp presently has a consensus target price of $308.00, indicating a potential upside of 18.71%. Quest Diagnostics has a consensus target price of $216.58, indicating a potential upside of 11.54%. Given Labcorp's stronger consensus rating and higher possible upside, equities analysts clearly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Labcorp and Labcorp both had 11 articles in the media. Quest Diagnostics' average media sentiment score of 1.06 beat Labcorp's score of 0.93 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.8%. Labcorp pays out 25.5% of its earnings in the form of a dividend. Quest Diagnostics pays out 38.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Labcorp beats Quest Diagnostics on 11 of the 18 factors compared between the two stocks.

How does Quest Diagnostics compare to DaVita?

DaVita (NYSE:DVA) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

90.1% of DaVita shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.5% of DaVita shares are owned by insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

DaVita has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

DaVita presently has a consensus target price of $199.17, indicating a potential upside of 2.26%. Quest Diagnostics has a consensus target price of $216.58, indicating a potential upside of 11.54%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Quest Diagnostics had 7 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Quest Diagnostics and 4 mentions for DaVita. Quest Diagnostics' average media sentiment score of 1.06 beat DaVita's score of 0.96 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has lower revenue, but higher earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.92	$746.80M	$10.78	18.07
Quest Diagnostics	$11.04B	1.95	$992M	$9.05	21.46

Quest Diagnostics has a net margin of 9.07% compared to DaVita's net margin of 5.65%. Quest Diagnostics' return on equity of 15.60% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Quest Diagnostics	9.07%	15.60%	7.06%

Summary

Quest Diagnostics beats DaVita on 11 of the 17 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$21.50B	$5.53B	$6.45B	$23.08B
Dividend Yield	1.79%	1.60%	2.69%	4.09%
P/E Ratio	21.46	32.83	22.30	31.02
Price / Sales	1.95	29.48	581.44	14.81
Price / Cash	12.67	15.97	42.31	24.78
Price / Book	3.00	3.08	9.84	4.67
Net Income	$992M	$218.81M	$3.57B	$1.07B
7 Day Performance	-0.04%	-2.48%	-1.16%	-0.67%
1 Month Performance	0.87%	-0.36%	3.85%	0.22%
1 Year Performance	11.82%	10.32%	27.40%	25.44%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	4.5381 of 5 stars	$194.17 +0.5%	$216.58 +11.5%	+10.7%	$21.50B	$11.04B	21.46	57,000	Positive News Insider Trade
HSIC Henry Schein	3.2961 of 5 stars	$76.40 -0.2%	$86.83 +13.7%	+9.3%	$8.72B	$13.38B	23.08	25,000
MEDP Medpace	2.1914 of 5 stars	$451.47 +1.0%	$467.08 +3.5%	+49.6%	$12.77B	$2.53B	28.38	6,200	Trending News Insider Trade
AMN AMN Healthcare Services	1.6146 of 5 stars	$29.47 +1.7%	$25.29 -14.2%	+48.2%	$1.12B	$2.73B	N/A	2,664	Analyst Revision Gap Down
LH Labcorp	3.9965 of 5 stars	$256.87 -1.2%	$308.00 +19.9%	+3.8%	$21.32B	$14.14B	22.75	71,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to DaVita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Which has more risk & volatility, DGX or HSIC?

Is DGX or HSIC more profitable?

Which has higher valuation and earnings, DGX or HSIC?

Does the media favor DGX or HSIC?

Do institutionals & insiders believe in DGX or HSIC?

Do analysts recommend DGX or HSIC?

Summary

How does Quest Diagnostics compare to Medpace?

Which has more volatility & risk, DGX or MEDP?

Which has better valuation & earnings, DGX or MEDP?

Is DGX or MEDP more profitable?

Do insiders & institutionals have more ownership in DGX or MEDP?

Do analysts recommend DGX or MEDP?

Does the media prefer DGX or MEDP?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Do insiders and institutionals have more ownership in DGX or AMN?

Is DGX or AMN more profitable?

Which has stronger earnings and valuation, DGX or AMN?

Do analysts recommend DGX or AMN?

Which has more risk & volatility, DGX or AMN?

Does the media refer more to DGX or AMN?

Is DGX or AMN a better dividend stock?

Summary

How does Quest Diagnostics compare to Labcorp?

Do institutionals & insiders have more ownership in LH or DGX?

Which has better earnings and valuation, LH or DGX?

Is LH or DGX more profitable?

Which has more risk & volatility, LH or DGX?

Do analysts prefer LH or DGX?

Does the media prefer LH or DGX?

Is LH or DGX a better dividend stock?

Summary

How does Quest Diagnostics compare to DaVita?

Do insiders and institutionals hold more shares of DVA or DGX?

Which has more risk and volatility, DVA or DGX?

Do analysts prefer DVA or DGX?

Does the media refer more to DVA or DGX?

Which has higher valuation & earnings, DVA or DGX?

Is DVA or DGX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools